Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
ONC212
CHF 0.00
Out of stock
NEW

Product Details | |
---|---|
Synonyms | TR-31; 7-Benzyl-4-(4-(trifluoromethyl)benzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; NSC-783745 |
Product Type | Chemical |
Properties | |
Formula | C24H23F3N4O |
MW | 440.5 |
CAS | 1807861-48-8 |
Source/Host Chemicals | Synthetic |
Purity Chemicals | ≥98% (HPLC) |
Appearance | Solid. |
Solubility | Soluble in DMSO. |
Declaration | Manufactured by Chemodex. |
Other Product Data |
Click here for Original Manufacturer Product Datasheet |
InChi Key | DFULPGUTXZTYKA-UHFFFAOYSA-N |
Smiles | O=C(N(CC1=CC=C(C(F)(F)F)C=C1)C2=NCCN23)C4=C3CCN(CC5=CC=CC=C5)C4 |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
Product Specification Sheet | |
Datasheet |
![]() |
Description
ONC212 is a potent imipridone small-molecule (and fluorinated imipridone analog of ONC201) that acts as a dual agonist of the mitochondrial protease ClpP and the orphan GPCR GPR132, provoking mitochondrial dysfunction, integrated stress response, and apoptotic cell death, particularly in acute leukemia and solid tumor models. By targeting the mitochondrial protease ClpP, this engagement disrupts mitochondrial function, impairs oxidative phosphorylation and contributes to its anti-tumor activity across diverse preclinical cancer models. Acting as an agonist of the orphan G protein-coupled receptor GPR132, triggering downstream Gαq signaling and the integrated stress response, contributes to its pronounced anti-leukemic effects, particularly in acute myeloid leukemia models.
Product References
(1) J. Wagner, et al.; Cell Cycle 16, 1790 (2017) | (2) T. Nii, et al.; Leukemia. 33, 2805 (2019) | (3) S. Jacques, et al.; Genetics 214, 1103 (2020) | (4) E.R. Bonner, et al.; Neuro. Oncol. 23, 542 (2021) | (5) N. Fatima, et al.; E. J. Heam. 2, 81 (2021) | (6) I, Ferrarini, et al.; Mol. Cancer Ther. 20, 1572 (2021) | (7) V. Basu, et al.; Cell Commun. Signal 22, 441 (2024)